Case Study

Assessing the Impact of EndoTool IV at UPMC Central Pennsylvania

Discover UPMC's approach to a 92% reduction in hypoglycemia, leveraging workflow enhancements and enhanced clinical results with EndoTool IV.

6 min read

Setting: UPMC Central Pennsylvania

Download PDF

The customer

UPMC Central Pennsylvania, a prominent healthcare institution, includes seven acute care hospitals, providing a total of 1,160 licensed beds. In addition, UPMC operates over 160 outpatient clinics and ancillary facilities. With a team of more than 2,900 physicians and allied health professionals, as well as approximately 11,000 dedicated employees, UPMC serves as a vital healthcare hub in central Pennsylvania.

Key findings

Significant Reduction in Hypoglycemia Rates
Hypoglycemia rate (<70 mg/dl) decreased from 1.9% to 0.53% (72% decline) after EndoTool IV implementation.
Reduced Time to Therapeutic Target
Time to reach desired glucose goal range decreased from 14.5 hours to 4.7 hours.
Decreased Frequency of Blood Glucose Measurements
22% decrease in blood glucose measurements while on an insulin infusion.

Challenge

UPMC Central Pennsylvania prioritized improving the care of hospitalized patients with diabetes for several years. The increasing complexity of care, along with workforce challenges, was further compounded by the COVID pandemic.

To address these issues, UPMC Central Pennsylvania, which is part of the larger UPMC system, implemented EndoTool IV insulin dosing software in July 2022.

Solution

UPMC Central Pennsylvania performed a three-month comparison before and after the implementation of EndoTool IV at one hospital. The analysis focused on patients treated for hyperglycemia and Diabetic Ketoacidosis, excluding COVID patients due to their smaller representation in the patient population after EndoTool IV implementation.

Results

A significant 72% decline in the hypoglycemia rate post EndoTool IV implementation.
Reduction in time to reach the desired glucose range, from 14.5 hours pre-implementation to just 4.7 hours post-implementation.

For patients with Diabetic Ketoacidosis (DKA):

A significant 92% reduction in the hypoglycemia rate.
A 25% decrease in time on insulin infusion.
A substantial reduction in the hospital stay length, from 7.3 days to 4.5 days.
In total, 2,862 patients were treated, and 74,000 blood glucose readings were documented, with a consistent low hypoglycemia rate of 0.45%